Kornimate/medical-research-clean huggingface dataset:
l-cysteine prevents stomach exposure to carcinogenic acetaldehyde

Conditions: Gastritis, Atrophic

Summary: atrophic gastritis with hypochlorhydric milieu is a risk factor for gastric cancer. microbes colonizing the acid-free stomach oxidize ethanol into acetaldehyde, a group 1 carcinogen. the aim is to assess gastric production of acetaldehyde and its inert condensation product, non-toxic 4-methyltiazolidine-2-carboxylic acid (mtca), after alcohol intake under treatment with slow-release l-cysteine or placebo. patients with biopsy-confirmed atrophic gastritis, low serum pepsinogen and high gastrin-17 are studied. on separate days, patients will be randomly assigned to receive 200 mg slow-release l-cysteine or placebo, then have intragastric instillation of 15% (0.3 g/kg) ethanol. after intake, gastric concentrations of acetaldehyde, ethanol, l-cysteine and mtca are analysed for 4 hours. expected results show mitigated exposure of the gastric mucosa to acetaldehyde.

gastric infection with helicobacter pylori induces chronic active gastritis which over the years develop atrophic gastritis with a hypochlorhydric milieu which is a risk factor for gastric cancer. microbes colonizing acid-free stomach oxidize ethanol into acetaldehyde, considered a group 1 carcinogen. the aim of the study is to assess the gastric production of acetaldehyde and its inert condensation product, non-toxic 4-methyltiazolidine-2-carboxylic acid (mtca), after alcohol intake under treatment with slow-release l-cysteine. identical placebo tablets will be used for comparison. patients with biopsy-confirmed atrophic gastritis, low serum pepsinogen and high gastrin-17 will be studied with case-control design. all subjects will be their own control. on separate days, patients are randomly assigned to receive 200 mg slow-release l-cysteine or placebo, then have intragastric instillation of 15% (0.3 g/kg) ethanol (corresponding to two glasses of wine). after intake, gastric sampling of fluid for a period of four hours is done and concentrations of acetaldehyde, ethanol, l-cysteine and mtca are analysed. l-cysteine is expected to decrease gastric acetaldehyde concentrations and increase the mtca level. gastric l-cysteine and mtca concentrations are expected to be maintained over the study period. with placebo, acetaldehyde is expected to be elevated along with ethanol concentrations. based on these assumptions slow-release l-cysteine binds acetaldehyde to form inactive mtca, which remains in gastric juice resulting in reduced local exposure of the gastric mucosa to carcinogenic acetaldehyde.

Eligibility criteria:
inclusion criteria: * helicobacter-associated chronic gastritis * hypochlorhydria * hypergastrinemia * hypopepsinogenemia exclusion criteria: * active peptic ulcer disease * other inflammatory gastrointestinal disease * gastrointestinal bleeding * gastrointestinal surgery * neurological disease * alcohol abuse * mental disorder * not able to sign informed consent

Keywords: atrohpic gastritis acetaldehyde ethanol l-cysteine
intraartecular platelet rich plasma for sacroiliitis

Conditions: Sacroiliitis

Summary: comparison between the effect of steroids and platelet-rich plasma on low back pain after ultrasound-guided sacroiliac injection to determine any is more effective and of long duration

a prospective randomized controlled study was conducted at the department of anesthesiology mansoura university hospital during the period from december 2017 to january 2019 on fifty asa i-iii adult patients, of both sex after approval of irb (institutional review board) id number ms17.10.03 \& irb date 12-11-2017. the patients were randomly allocated into two groups each of 25 patients according to computer-generated random number codes that were placed in sealed envelopes, double blinded, with parallel-group comparison. steroid group (s) (n. 25):- patients were injected by 4 ml of sterile water containing the methylprednisolone acetate (depo-medrol) per-kg calculated dose (0.5mg/kg up to a lean muscle body weight of 80kg in the painful sacroiliac joint). platelet rich plasma group (p) (n. 25):-patients received fixed volume of 4 ml platelet-rich plasma in the inflamed painful sacroiliac joint.

Eligibility criteria:
inclusion criteria: * 1. patients of either sex. 2. asa i\&iii. 3. age between 18 - 70 years. 4. chronic lower back pain of sacroiliac origin. 5. anatomy of the joint can identified by the ultrasonography. exclusion criteria 1. patients with contraindications to sacroiliac injection. 2. patients known to be allergic to platelet rich plasma or local anesthetics. 3. history of immune suppression or immune compromised diseases 4. patient below age of 18 as the joint will undergo normal physiological changes. 5. patient over 70 years. 6. sacroiliac pain of multiple sources. 7. preoperative shivering or fever (\>38oc). 8. hepatic, renal and heart failure patients. 9. patients on; anticoagulants, antiplatelet, and with inr≥1.5. 10. exclude corticosteroid injection in the sacroiliac joint at the last three months. 11. patient refusal.

Keywords: platelet reach plasma sacroiliac ultrasound steroid chronic low back pain
neoadjuvant slot versus sox in patients with locally advanced, resectable gastric/esophagogastric junction (egj) cancer

Conditions: Gastric Adenocarcinoma

Summary: gastric cancer is a highly aggressive malignancy with a poor overall outcome. the purpose of this study is to evaluate the 5-year survival of neoadjuvant s1, oxaliplatin, and docetaxel (slot) versus s1, oxaliplatin(sox) in patients with locally advanced, resectable gastric/esophagogastric junction (egj) cancer.

two arms, phase 3 study of neoadjuvant s1, oxaliplatin, and docetaxel (slot) versus s1, oxaliplatin(sox) in patients with locally advanced, resectable gastric/esophagogastric junction (egj) cancer. 380 patients will be enrolled in this trial. the primary objective of this study is to determine the 5-year survival of the two arms.

Eligibility criteria:
inclusion criteria: * histologically proven gastric or ge junction adenocarcinoma; * age: 18 to 70; * ecog 0-2; * adenocarcinoma of the stomach or ge junction according to staging classification tnm scannographic: t3-4 n0/n + m0 ; * completion of baseline quality of life questionnaire * adequate bone marrow functions (anc ≥ 1,500/ul, blood platelet ≥ 100,000/ul, haemoglobin ≥ 10g/dl); * adequate renal functions(serum creatinine ≤ 1.5mg/dl) * liver functions (serum bilirubin ≤ 1.5unl, ast/alt ≤ 3 times(normal value) * written informed consent exclusion criteria: * previous chemotherapy; * active infection requiring antibiotics * pregnant, lactating women * psychiatric illness, epileptic disorders * concurrent systemic illness not appropriate for chemotherapy * history of other malignancy within 5 years except for non-melanoma skin cancer, cervix in situ carcinoma
refeeding like syndrome in acute disease

Conditions: Refeeding Syndrome; Acute Abdomen

Summary: the refeeding syndrome has been reported without any evidence of prolopnged semistarvation, thus being different from the traditional disease. the investigators wanted to investigate, if sodium infusions could be part of the explanation.

background: refeeding syndrome is conventionally connected to start of feeding after prolonged periods of semi-starvation and adaption. however, it is also described in acutely ill patients and in icu patients without a history of adaption, but sometimes only defined as a drop in p-phosphate without clinical manifestations. the investigators hypothesize, that a positive sodium balance could induce the refeeding-like syndrome (rls). method: consecutive patients for acute, abdominal surgery were included and observed until discharge or up to seven days postoperatively with daily sodium and phosphate balance measurements.

Eligibility criteria:
inclusion criteria: * age \> 18 yr * ready for acute surgery * able to understand and cooperate. exclusion criteria: * pregnancy or breastfeeding * renal insufficiency (p-creatinine\>400 micr mol/l) * re-operations * expected hospital stay \< 24 hours.

Keywords: refeeding syndrome acute abdominal disease
conservative treatment compared to osteosynthesis in patients with a fractured collar bone

Conditions: Displaced Midshaft Fracture of the Collar Bone

Summary: this study will compare non-operative treatment of displaced midshaft collarbone fractures with operative treatment using a precontoured titanium plate and screws. the study hypothesis is that operation will provide better pain relief, faster return to activities, better function of the involved upper limb, and lower the risk of a non healing fracture (non union).


Eligibility criteria:
inclusion criteria: * fracture located to the mid third of the collar bone where there is no contact between the fractured surface of the main fragments on x-ray in one or two of two levels. exclusion criteria: * bilateral fracture * imminent skin perforation * open fracture * associated neurovascular effect * unstable fracture of neck of scapula "floating shoulder" * fracture of coincidental upper extremity distal for the shoulder * pathologic fracture * the patient states that there was a unilateral or bilateral shoulder problem before the fracture * fracture realized more than 14 days after it arose * circumstances which make it impossible to carry out one of the two regimes, i.e. mental illness and abuse * circumstances which make follow-up impossible, i.e. address far from the including departments and stays abroad of long duration * medical contraindication against surgery or general anaesthesia * former participation in the trial * former fracture contra/ipsilateral at the age of 15 or older

Keywords: fracture collar bone
biomarker and dna collection in subjects participating in protocol 22003

Conditions: Fragile X Syndrome

Summary: the subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003a which will evaluate secreted protein before and after treatment with stx209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with stx209. these same subjects will also be asked to contribute a blood sample for dna (deoxyribonucleic acid) collection. the investigators will study the dna to determine if stx209 works better in people with specific gene variations, or to find new gene variations that predict how well stx209 works.


Eligibility criteria:
inclusion criteria: * the autism spectrum disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 exclusion criteria: * the autism spectrum disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003

Keywords: fragile x syndrome biomarkers
safety and immunogenicity of different meningitis vaccine formulations in adolescents and young adults

Conditions: Invasive Meningococcal Disease

Summary: this study will evaluate the safety and immunogenicity of combination vaccines as compared to the reference vaccines


Eligibility criteria:
inclusion criteria: * healthy adolescents aged 10 through 25 years of age inclusive at the time of enrollment. exclusion criteria: * history of any meningococcal vaccine administration; * current or previous, confirmed or suspected disease caused by n. meningitidis; * pregnant or nursing (breastfeeding) mothers; * females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study; * any serious, chronic, or progressive disease; * known or suspected impairment/alteration of the immune system; * receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days; * history of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component.

Keywords: safety immunogenicity vaccine meningococcal seroresponse
pharmacodynamic effects of a free-fatty acid formulation of omega-3 pentaenoic acid in adults with hypertriglyceridemia

Conditions: Hypertriglyceridemia

Summary: pharmacodynamic effects of mat9001 compared to vascepa in adults with hypertriglyceridemia

an open-label, randomized, crossover study to assess the pharmacodynamic effects of mat-9001, an omega-3 free fatty acid compared to vascepa (icosapent ethyl) on triglycerides and other lipoprotein lipids in men and women with elevated triglycerides.

Eligibility criteria:
inclusion criteria: * male or female, ≥18 y of age * judged to be in generally good health * fasting triglycerides ≥150 mg/dl to ≤499 mg/dl during screening * body mass index of ≥20.0 kg/m2 * no clinically significant findings in a 12-lead ecg or physical examination * willing and able to undergo the scheduled study procedures * understands study procedures and signs forms documenting informed consent to participate in the study exclusion criteria: * laboratory test result of clinical significance * uncontrolled hypertension * clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder * history of human immunodeficiency virus, hepatitis b or hepatitis c infection * used any medication intended to alter the lipid profile within 4 weeks of the first qualification visit * active systemic infection * a condition the investigator believes would interfere subject ability to provide informed consent and/or comply with the study protocol
the effect of anesthetics on oxidative stress and apoptosis status in children

Conditions: Anesthesia, General

Summary: the purpose of this study is to determine whether propofol and sevoflurane affect the oxidative stress and apoptosis status in children undergoing hypospadias repair surgery.


Eligibility criteria:
inclusion criteria: * american society of anesthesiology (asa) i-ii, undergoing selective surgery for hypospadias repair. exclusion criteria: * a history of developmental delay or mental retardation, which could make observational pain intensity assessment outside the norm; * a history of central nervous system diseases; * a known or suspected coagulopathy; * a known allergy to any of the study drugs; * abnormalities of the sacrum and any signs of infection at the site of the proposed caudal block.
nation-wide health resource consumption and costs associated with mepolizumab

Conditions: Asthma

Summary: currently, no study has addressed real-life data describing changes in health resource consumption and related costs attributable to mepolizumab treatment. the aim of the current study is to fill this knowledge gap by performing an exhaustive extraction of data for patients receiving mepolizumab in the french single-payer health care system. the change in real-life health-resource usage and costs observed for these patients would provide the first evidence that mepolizumab is changing the care landscape for eligible severe asthma patients. the overall objectives of this study are: (i) using the snds french national database, to identify a representative, nation-wide population of patients treated with mepolizumab with a follow-up period of at least 12 months, (ii) to describe the initial one-year changes in health resource use before and after the initiation of mepolizumab treatment and (iii) to estimate the change in associated costs for the first year of treatment. these initial data will additionally serve as a basis for the design of longer-term studies. primary objective: to estimate the change in associated costs for the first year of treatment

secondary objectives: * to describe the initial one-year changes in health resource use before and after the initiation of mepolizumab treatment * to further characterize rates of change in health resource usage and/or costs in subpopulations of interest (sex, age groups, severe asthma, uncontrolled asthma, copd, diabetes) this retrospective, non-interventional (not involving human subjects) database study will compare real-life patient health resource consumption before versus after a first injection of mepolizumab. data concerning patients receiving mepolizumab will be collated for a 12-month period (the "baseline period") preceding a first index treatment (at "t0") and compared to a 12-month period occurring after the index treatment (the "exposure period").

Eligibility criteria:
inclusion criteria: * beneficiary in the anonymous french national snds database * the beneficiary received mepolizumab exclusion criteria: * health resource use data covering the 12 months preceding the first filled prescription for mepolizumab are not available * health resource use data covering the time period starting at the first filled prescription for mepolizumab and ending at subsequent death or at 12 months later are not available

Keywords: mepolizumab
study of ruxolitinib cream for the treatment of discoid lupus erythematosus

Conditions: Discoid Lupus Erythematosus

Summary: the purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (dle)


Eligibility criteria:
inclusion criteria: * ability to understand and comply with the protocol and provide informed consent. * speaks english. * age ≥ 18 years. * clinical diagnosis of discoid lupus as assessed by the pi. * at least one active (inflamed) discoid lesion with an iga score of ≥ 3 and with a diameter ≥ 1cm at screening and baseline. two lesions with equal scores will be necessary if consenting to pre-and post-treatment biopsies. * maximum body surface area of 20%. exclusion criteria: * unwillingness or inability to complete informed consent process or comply with the study protocol. * pregnant or breast-feeding women, or women planning to become pregnant or breastfeed during the study. * history of coagulopathy, pulmonary embolism or deep venous thrombosis. * history of cutaneous squamous cell carcinoma localized to the treatment area. * serum creatinine \> 1.5 mg/dl, or alanine aminotransferase or aspartate aminotransferase \> 1.5 × upper limit of normal. * other dermatologic disease besides discoid lupus whose presence or treatments could complicate assessments. * other diseases besides dermatologic disorders whose treatment could complicate assessments. subjects with systemic lupus erythematosus are permitted as long as they do not have unstable disease and meet all other criteria, including the exclusion criteria for systemic immunosuppressive or immunomodulating drugs (below). * topical treatments for discoid lupus within 2 weeks of visit 2. * systemic immunosuppressive or immunomodulating drugs (e.g. oral or injectable corticosteroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine) other than antimalarials (hydroxychloroquine, chloroquine, quinacrine) within 4 weeks or 5 half-lives of visit 2 (whichever is longer). * potent systemic cytochrome p450 3a4 inhibitors or fluconazole within 2 weeks or 5 half-lives, whichever is longer, before visit 2 (topical agents with limited systemic availability are permitted). * prior use of jak inhibitors, systemic or topical, within the last 12 months. * ultraviolet (uv) therapy or tanning within 2 weeks prior to visit 2 or during the duration of the treatment period. * any systemic or local infection that, in the opinion of the investigator, may compromise the safety of the subject or complicate assessments. * subjects allergic to lidocaine or with a history of keloids will not be allowed to provide an optional skin biopsy, but will be eligible for the remainder of the study. * electrocardiogram (ecg) changes on baseline screening consistent with high risk for a major adverse cardiovascular event (mace).
machine learning for recurrence risk of pancreatic cancer after radical resection

Conditions: Pancreatic Cancer

Summary: recurrence of pancreatic cancer(pca) is a multifactorial event. based on the clinicopathological characteristics and imaging data of patients with pca, the investigators used image processing and machine learning algorithms to build a more comprehensive and robust model, and added some unused features to explore its clinical application value. a retrospective analysis of patients with pca who underwent radical resection at zhejiang cancer hospital (hangzhou, china) from january 2013 to december 2020. the database was extracted from the preoperative demographics, blood markers, and surgical pathology information of patients undergoing radical pca surgery in the investigators' hospital. the investigators used the pyradiomics platform to extract image features.


Eligibility criteria:
inclusion criteria: * have the results of enhanced ct examination of the pancreas within 1 month before surgery in our hospital; * radical resection of pancreatic cancer was performed in our hospital; * there are follow-up results in our hospital, and the follow-up endpoints include disease recurrence or at least 12 months. * complete clinical medical records and imaging data. exclusion criteria: * non-r0 resection; * combined with other malignant tumors * the patient's imaging data has technical problems or the lesion is too small (less than 1cm), which is not suitable for omics analysis.
renal allograft tolerance through mixed chimerism - smc/mgh

Conditions: Renal Failure

Summary: the goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without chimerism transition syndrome (cts), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.


Eligibility criteria:
inclusion criteria: * male or female 18-65 years of age. * candidate for a living-donor renal allograft from an hla mismatched donor * subjects with chronic kidney disease stage or esrd who are treated with either hemodialysis or peritoneal dialysis. * first transplant. * use of fda-approved methods of contraception * ability to understand and provide informed consent. * negative covid at screening and 2 days before procedure exclusion criteria: * abo blood group-incompatible renal allograft. * participant with a (non dsa) pra \> 20% within 6 months prior to transplant * persistent leukopenia (wbc less than 2,000/mm3) or thrombocytopenia (\<100,000/mm3). * seropositivity for hiv-1, hepatitis b core antigen, or hepatitis c virus (confirmed by hepatitis c virus rna); or positivity for hepatitis b surface antigen. * active infection * left ventricular ejection fraction \< 40% as determined by tte or clinical evidence of heart failure * forced expiratory volume fev1 or dlco \< 50% of predicted. * lactation or pregnancy * history of cancer (following the american transplant society guidelines) * underlying renal disease etiology with a high risk of disease recurrence in the transplanted kidney (such as focal segmental glomerulosclerosis). * prior dose-limiting radiation therapy * known genetic disease or family history that may result in greater sensitivity to the effects of irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during the irradiation component of the conditioning regimen * enrollment in other investigational drug studies within 30 days prior to enrollment * abnormal (\>2 times lab normal) values for (a) liver function chemistries (alt, ast, ap), (b) bilirubin, (c) coagulation studies (pt, ptt). * allergy or sensitivity to any component of siplizumab, fludarabine, cyclophosphamide, tacrolimus, dmso, mmf or rituximab. * the presence of any medical condition that the investigator deems incompatible with participation in the trial. * subjects who have non-insulin dependent diabetes (niddm) without good blood glucose control (hba1c\<7). subject with severe retinopathy, gastroparesis, or severe neuropathy which prevent subject's normal independent daily activities will be excluded from the study